17-Hydroxyprogesterone - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

17-Hydroxyprogesterone

The Experts below are selected from a list of 171 Experts worldwide ranked by ideXlab platform

17-Hydroxyprogesterone – Free Register to Access Experts & Abstracts

David E. Kime – One of the best experts on this subject based on the ideXlab platform.

  • Biosynthesis of 17,20α-Dihydroxy-4-pregnen-3-one, 17,20β-Dihydroxy-4-pregnen-3-one, and 11-Ketotestosterone by Testicular Fragments and Sperm of the Roach, Rutilus rutilus
    General and Comparative Endocrinology, 1995
    Co-Authors: Mansour Ebrahimi, Pratap B. Singh, David E. Kime
    Abstract:

    Abstract The effect of incubation time and substrate concentration on the in vitro metabolism of 17-Hydroxyprogesterone by testes of the roach has been examined. There was a shift from synthesis of the 11-oxygenated androgens, 11-ketotestosterone, and androstenetrione at low substrate concentration to 17,20α-dihydroxy-4-pregnen-3-one (17,20αP) at high substrate. Glucuronides and sulfates were of significant importance only at low substrate and long incubation times. There was a shift from 17,20β-dihydroxy-4-pregnen-3-one to 17,20αP with increased substrate. The results confirm that substrate affects the steroidogenic profile and that 3 hr is optimal time for such studies. Incubations of sperm with 17-Hydroxyprogesterone gave predominantly 11-ketotestosterone at low substrate concentrations and 17,20αP at high substrate. The synthesis of 11-ketotestosterone is demonstrated for the first time in teleost sperm.

  • Substrate concentration affects the in vitro metabolism of 17-Hydroxyprogesterone by ovaries of the carp, Cyprinus carpio.
    Fish physiology and biochemistry, 1994
    Co-Authors: David E. Kime, Mohammad A.s. Abdullah, Miroslawa Sokolowska-mikolajczyk, P. Epler
    Abstract:

    Carp ovarian tissue was incubated with (3)H-17-Hydroxyprogesterone in the presence of 0, 0.1, 1, 10, and 100 μg ml(-1) unlabeled 17-Hydroxyprogesterone. The pattern of metabolites formed showed a marked variation with substrate concentration. Formation of glucuronide and sulphate conjugates was important only at low substrate concentration. At high substrate concentration (10 and 100 μg ml(-1)) 17,20α-dihydroxy-4-pregnen-3-one was the major metabolite, but at intermediate concentrations polar 7α-hydroxypregnanetetrols predominated. The results support the hypothesis that at low substrate concentrations conjugating, 5α-reducing and 7α-hydroxylating enzymes, of high activity but low capacity, act as scavengers to deactivate any steroids formed during the relatively low pituitary gonadotrophin secretions which are necessary for oocyte development, but that during the prespawning gonadotrophin surge when high levels of substrate are present these enzymes are saturated and 17,20α-dihydroxy-4-pregnen-3-one (17,20αP) becomes the major ovarian steroid. The possible role of 17,20αP during oocyte final maturation requires further examination.

Steve N Caritis – One of the best experts on this subject based on the ideXlab platform.

  • Quality Assessment of Compounded 17-Hydroxyprogesterone Caproate
    American journal of obstetrics and gynecology, 2013
    Co-Authors: Justine Chang, Raman Venkataramanan, Yang Zhao, Wenchen Zhao, Steve N Caritis
    Abstract:

    The purpose of this study was to evaluate the quality of compounded 17-Hydroxyprogesterone caproate (17-OHPC). Compounded 17-OHPC that was obtained from 15 compounding pharmacies throughout the United States was analyzed for potency, impurities, sterility, and pyrogen status. Eighteen samples were supplied by 15 compounding pharmacies. The concentration of 17-OHPC in all samples was within the specification limits, and all tested samples passed sterility and pyrogen testing. Only 1 of 18 samples was out of specification limits for impurities. Compounded 17-OHPC that was obtained from 15 pharmacies throughout the United States did not raise safety concerns when assessed for potency, sterility, pyrogen status, or impurities. Copyright © 2014 Mosby, Inc. All rights reserved.

  • effect of endogenous steroid hormones on 17 alpha hydroxyprogesterone caproate metabolism
    American Journal of Obstetrics and Gynecology, 2013
    Co-Authors: Courtney D Cuppett, Yang Zhao, Steve N Caritis, Shimin Zhang, Wenchen Zhao, Raman Venkataramanan
    Abstract:

    Objective Plasma concentrations of 17-alpha-hydroxyprogesterone caproate (17-OHPC) vary substantially in pregnant patients who receive an identical dose. Endogenous steroid hormones may alter 17-OHPC metabolism, which contributes to this large variability. Study Design Pooled human liver microsomes were incubated with 17-OHPC alone or in combination with progesterone, hydroxyprogesterone, estrone, estradiol, or estriol. High-performance liquid chrochromatography with ultraviolet detection was used to quantify 17-OHPC. Results Under the conditions that were studied, 17-OHPC metabolism was inhibited by 37% by a combination of endogenous steroid hormones. Progesterone alone significantly inhibited 17-OHPC metabolism by 28% ( P Conclusion 17-OHPC metabolism is inhibited significantly by endogenous steroids and, in particular, progesterone. This effect may account for some of the large variation in plasma 17-OHPC concentrations that is seen in pregnant patients who receive a fixed dose of medication.

  • Pharmacology and placental transport of 17-Hydroxyprogesterone caproate in singleton gestation
    American journal of obstetrics and gynecology, 2012
    Co-Authors: Steve N Caritis, Raman Venkataramanan, Shringi Sharma, Gary D.v. Hankins, Menachem Miodovnik, Mary F. Hebert, Jason G. Umans, Thomas J. Benedetti, Donald R. Mattison, Anne Zajicek
    Abstract:

    The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-Hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks’ gestation (study 1) and 31 + 0 to 34 + 6 weeks’ gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier. Copyright © 2012 Mosby, Inc. All rights reserved.

Raman Venkataramanan – One of the best experts on this subject based on the ideXlab platform.

  • Quality Assessment of Compounded 17-Hydroxyprogesterone Caproate
    American journal of obstetrics and gynecology, 2013
    Co-Authors: Justine Chang, Raman Venkataramanan, Yang Zhao, Wenchen Zhao, Steve N Caritis
    Abstract:

    The purpose of this study was to evaluate the quality of compounded 17-Hydroxyprogesterone caproate (17-OHPC). Compounded 17-OHPC that was obtained from 15 compounding pharmacies throughout the United States was analyzed for potency, impurities, sterility, and pyrogen status. Eighteen samples were supplied by 15 compounding pharmacies. The concentration of 17-OHPC in all samples was within the specification limits, and all tested samples passed sterility and pyrogen testing. Only 1 of 18 samples was out of specification limits for impurities. Compounded 17-OHPC that was obtained from 15 pharmacies throughout the United States did not raise safety concerns when assessed for potency, sterility, pyrogen status, or impurities. Copyright © 2014 Mosby, Inc. All rights reserved.

  • effect of endogenous steroid hormones on 17 alpha hydroxyprogesterone caproate metabolism
    American Journal of Obstetrics and Gynecology, 2013
    Co-Authors: Courtney D Cuppett, Yang Zhao, Steve N Caritis, Shimin Zhang, Wenchen Zhao, Raman Venkataramanan
    Abstract:

    Objective Plasma concentrations of 17-alpha-hydroxyprogesterone caproate (17-OHPC) vary substantially in pregnant patients who receive an identical dose. Endogenous steroid hormones may alter 17-OHPC metabolism, which contributes to this large variability. Study Design Pooled human liver microsomes were incubated with 17-OHPC alone or in combination with progesterone, hydroxyprogesterone, estrone, estradiol, or estriol. High-performance liquid chromatography with ultraviolet detection was used to quantify 17-OHPC. Results Under the conditions that were studied, 17-OHPC metabolism was inhibited by 37% by a combination of endogenous steroid hormones. Progesterone alone significantly inhibited 17-OHPC metabolism by 28% ( P Conclusion 17-OHPC metabolism is inhibited significantly by endogenous steroids and, in particular, progesterone. This effect may account for some of the large variation in plasma 17-OHPC concentrations that is seen in pregnant patients who receive a fixed dose of medication.

  • Pharmacology and placental transport of 17-Hydroxyprogesterone caproate in singleton gestation
    American journal of obstetrics and gynecology, 2012
    Co-Authors: Steve N Caritis, Raman Venkataramanan, Shringi Sharma, Gary D.v. Hankins, Menachem Miodovnik, Mary F. Hebert, Jason G. Umans, Thomas J. Benedetti, Donald R. Mattison, Anne Zajicek
    Abstract:

    The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-Hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks’ gestation (study 1) and 31 + 0 to 34 + 6 weeks’ gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier. Copyright © 2012 Mosby, Inc. All rights reserved.